Virtus ETF Advisers LLC Allovir, Inc. Transaction History

Virtus ETF Advisers LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.94 - $7.05 $22,891 - $40,960	-5,810 Reduced 27.79%	15,096 $59,000
Q4 2022 Feb 14, 2023	BUY	$4.7 - $9.98 $98,258 - $208,641	20,906 New	20,906 $107,000
Q2 2022 Aug 12, 2022	SELL	$3.26 - $7.06 $34,109 - $73,868	-10,463 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$6.75 - $13.52 $4,137 - $8,287	-613 Reduced 5.53%	10,463 $71,000
Q4 2021 Feb 14, 2022	BUY	$12.94 - $25.99 $22,217 - $44,624	1,717 Added 18.35%	11,076 $143,000
Q3 2021 Nov 15, 2021	SELL	$16.97 - $25.06 $8,400 - $12,404	-495 Reduced 5.02%	9,359 $235,000
Q2 2021 Aug 10, 2021	BUY	$19.44 - $25.06 $46,189 - $59,542	2,376 Added 31.77%	9,854 $195,000
Q1 2021 May 17, 2021	BUY	$20.81 - $45.5 $2,892 - $6,324	139 Added 1.89%	7,478 $175,000
Q4 2020 Feb 12, 2021	BUY	$23.94 - $46.81 $175,695 - $343,538	7,339 New	7,339 $282,000

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $49.3M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.